J.M. Berger, P. Gattinger and A.S. Berghoff, and declare that they have no competing interests. M.J. Mair reported receiving nonfinancial support from Pierre Fabre outside the submitted work. R. Valenta reported receiving personal fees from Viravaxx AG and Worg Pharmaceuticals; receiving grants from HVD Biotech, Viravaxx AG, and Worg Pharmaceuticals outside the submitted work; and holding a patent for Molecular Interaction Assay (pending) and a patent for SARS-CoV‑2 vaccine (pending). M. Preusser reported receiving personal fees from Bayer, Bristol Myers Squibb, Novartis, Gerson Lehrman Group, CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, AstraZeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dohme, Tocagen, Adastra, and Gan & Lee Pharmaceuticals outside the submitted work. No other disclosures were reported.

This study was funded by the Austrian Federal Ministry for Digital and Economic Affairs; the National Foundation for Research, Technology and Development; and the Christian Doppler Research Association. This study was also funded from the research budget of the Medical University of Vienna. The funding organizations had no role/influence in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.